Quince Therapeutics, Inc.

NasdaqGS:QNCX Stock Report

Market Cap: US$48.0m

Quince Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:QNCX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
30 Aug 24BuyUS$107,375Dirk ThyeIndividual154,500US$0.70
21 Aug 24BuyUS$24,166Brendan HannahIndividual38,924US$0.63
20 Aug 24BuyUS$31,452Charles RyanIndividual48,387US$0.65

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of QNCX?
Owner TypeNumber of SharesOwnership Percentage
Public Companies189,1220.43%
VC/PE Firms2,806,6116.38%
Individual Insiders5,777,51813.1%
Institutions6,087,36413.8%
General Public29,141,02866.2%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 33.45% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.96%
David Lamond
4,384,096US$4.8m0%no data
6.38%
Genextra S.p.A.
2,806,611US$3.1m11.1%100.0%
2.89%
The Vanguard Group, Inc.
1,272,340US$1.4m6.06%no data
2.72%
Sofinnova Partners SAS
1,197,711US$1.3m-50.1%1.09%
1.95%
Dirk Thye
860,165US$937.6k1.92%no data
1.87%
EPIQ Capital Group, LLC
824,782US$899.0k-0.14%0.23%
1.19%
Renaissance Technologies LLC
523,050US$570.1k0.09%no data
0.85%
Geode Capital Management, LLC
375,932US$409.8k10.9%no data
0.79%
BlackRock, Inc.
345,448US$376.5k-22.9%no data
0.78%
HighTower Advisors, LLC
341,570US$372.3k0%no data
0.69%
Brendan Hannah
304,652US$332.1k2.74%no data
0.63%
Shay Capital LLC
276,799US$301.7k60.8%0.08%
0.43%
Alphabet Inc.
189,122US$206.1k0%no data
0.32%
ADAR1 Capital Management, LLC
142,958US$155.8k0%0.03%
0.28%
State Street Global Advisors, Inc.
124,911US$136.2k121%no data
0.28%
Mariner, LLC
122,461US$133.5k0%no data
0.28%
Charles Ryan
122,461US$133.5k0%no data
0.21%
Bridgeway Capital Management, LLC
92,317US$100.6k4.32%no data
0.21%
Scharf Investments, LLC
91,061US$99.3k0%no data
0.18%
Luca Benatti
80,261US$87.5k0%no data
0.17%
Morgan Stanley, Investment Banking and Brokerage Investments
74,434US$81.1k1,090%no data
0.12%
Intellectus Partners, LLC
53,312US$58.1k0%0.01%
0.11%
Northern Trust Global Investments
50,524US$55.1k48.5%no data
0.069%
Two Sigma Investments, LP
30,341US$33.1k0%no data
0.066%
Virtu Financial LLC, Asset Management Arm
29,204US$31.8k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/06 18:14
End of Day Share Price 2025/05/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Quince Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tazeen AhmadBofA Global Research
Kumaraguru RajaBrookline Capital Markets
Sumant Satchidanand KulkarniCanaccord Genuity